UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
MEDICAL DEVICES, DIAGNOSTICS & EQUIPMENT

Oertli Instrumente

Swiss manufacturer of ophthalmic surgical systems and instruments

Oertli Instrumente logo

Oertli Instrumente

Swiss manufacturer of ophthalmic surgical systems and instruments

Visit Website

About Oertli Instrumente

Oertli Instrumente has been engineering precision ophthalmic surgical systems from Switzerland for more than seven decades, establishing itself as a specialist in the technology that surgeons depend on for cataract, vitreoretinal, and anterior segment procedures.

Based in Berneck, the company designs and manufactures phacoemulsification and vitreoretinal platforms used in operating theatres worldwide. Its product portfolio centres on surgical consoles, handpieces, and accessories built to the exacting standards that microsurgery demands. The focus on ophthalmology as a single discipline allows Oertli to develop deep technical expertise in fluidics, ultrasound delivery, and integrated surgical control, rather than spreading development resource across multiple therapeutic categories.

Oertli's systems are distributed across Europe, Asia, and the Americas, with a network of clinical and technical support that reflects the company's emphasis on long-term relationships with surgical teams. The privately held structure keeps decision-making close to the engineering and clinical teams, a model the company has sustained through successive generations of platform development.

The OS 4 surgical system is among its most recognised platforms, integrating cataract and vitreoretinal functionality within a single console. This kind of consolidation is increasingly valued in ophthalmic theatres where space, workflow efficiency, and consistent performance across procedure types are operational priorities.

Further information is available at oertli-instruments.com.

Areas of Expertise

Cataract SurgeryOphthalmologySurgical DevicesVitreoretinal Surgery

Services & Capabilities

Cataract SurgeryOphthalmologySurgical DevicesVitreoretinal Surgery
Similar Companies

More in Medical Devices, Diagnostics & Equipment

R

Roche

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology, haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.

View profile
A

Aerogen

With technology deployed in more than 80 countries and used to treat over 30 million patients, Aerogen has established itself as the global leader in acute care aerosol drug delivery. Founded in Galway, Ireland, the company built its reputation on a single, well-defined mission: ensuring that critically ill patients receive inhaled medication reliably, precisely, and without disrupting the ventilation or oxygenation they depend on.Vibrating Mesh Nebuliser PlatformThe company's core technology is the vibrating mesh nebuliser, a platform protected by more than 300 international patents and referenced in over 300 clinical publications. At the heart of the system is a mesh containing thousands of precision-formed apertures that act as a micropump, converting liquid medication into a fine, low-velocity aerosol optimised for deep lung deposition. The Aerogen Solo, the flagship single-patient-use device, is integrated into ventilator platforms from GE Healthcare, Draeger, Philips, Covidien, and virtually every major manufacturer of critical care ventilators, making it the de facto standard across intensive care units worldwide.One System Across the Respiratory JourneyA defining feature of the Aerogen portfolio is its continuity of care design. A single Aerogen Solo device supports patients across every stage of their hospital respiratory journey, from invasive mechanical ventilation in the ICU through non-invasive ventilation, high-flow nasal cannula therapy, and self-ventilating recovery, without the need to change hardware or recalibrate dosing. The Aerogen Ultra extends this flexibility by providing a handheld option for ambulatory or step-down settings. The continuous nebulisation tube set rounds out the range, enabling extended, precisely controlled drug administration where sustained dosing is clinically indicated.Aerogen operates internationally, with facilities in Galway, Ireland, and commercial presence across North America, Europe, and Asia-Pacific. The company supports a broad formulary of inhaled agents, including bronchodilators, corticosteroids, mucolytics, and antimicrobials, reflecting the breadth of pharmacological need in acute respiratory care.Further information is available at aerogen.com.

View profile
A

ASPIVIX

Aspivix is the Swiss medical device company behind carevix®, the world's first suction-based cervical stabiliser and a device named one of TIME magazine's Best Inventions of 2024. Founded in 2015 and headquartered in Renens, Switzerland, the company was built around a single, clear purpose: replacing the tenaculum, a sharp-tipped instrument that has been used in gynaecology for more than a century, with a gentler, atraumatic alternative.The carevix® device affixes to the cervix via soft suction rather than by piercing tissue, and has been shown in clinical studies to reduce pain during IUD insertion by more than 70% and bleeding by over 80% compared with traditional tenaculum use. The device has received FDA 510(k) clearance, CE Mark, MHRA approval, and ANVISA registration, enabling commercialisation across Switzerland, the United States, the United Kingdom, and the Benelux region. Initial US availability expanded into Southern California and New York following the FDA clearance issued in January 2023.Aspivix's commercial partnerships include collaboration with Bayer, the leading global IUD manufacturer, for the Swiss market rollout. The company has raised funding from a range of European investors, including a $5 million Series A+ round backed by HEMEX, 4FOx Ventures, and Zürcher Kantonalbank, alongside a EUREKA-EUROSTARS grant co-funded by Innosuisse. Its focus remains on women's health innovation, specifically transcervical procedures such as IUD insertion, hysteroscopy, cervical biopsy, and fertility treatments.Further information is available at aspivix.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy